What infusion reactions occur with Kevzara?
Kevzara (sarilumab), used for rheumatoid arthritis, is given by subcutaneous injection, not intravenous infusion. No infusion reactions are reported because it lacks an IV formulation.[1]
Why no infusion reactions?
The drug's delivery avoids IV risks like cytokine release or hypersensitivity during infusion. Clinical trials and post-marketing data focus on injection-site reactions instead, such as redness, itching, or swelling at the subcutaneous site, affecting up to 10% of patients.[1][2]
Common injection-site reactions patients report
- Erythema (redness): Most frequent, mild to moderate.
- Pruritus (itching).
- Edema (swelling).
- Pain or bruising.
These typically resolve without stopping treatment. Severe cases are rare (<1%).[2]
How do they compare to IV biologics like Rituxan?
Unlike IV drugs (e.g., rituximab), Kevzara skips infusion-related events like chills, fever, or hypotension, which hit 20-30% of patients in first doses. Subcutaneous biologics like Kevzara have lower acute reaction rates overall.[3]
When to watch for serious hypersensitivity
Monitor for signs like rash, urticaria, or angioedema post-injection. Anaphylaxis is possible but uncommon (0.1-0.3%). Premedication isn't standard; hold doses if severe.[1][2]
What do trial data show on reaction rates?
Phase 3 trials (MOBILITY, TARGET) reported injection-site reactions in 7-11% of Kevzara users vs. 5% on placebo. No increase with dose (150mg or 200mg every 2 weeks).[2]
[1]: Kevzara Prescribing Information (Sanofi/Regeneron)
[2]: FDA Label for Kevzara
[3]: Drugs.com - Kevzara Side Effects